- Opinion
- [Column] The inconvenient truth of ATP survey
- by Eo, Yun-Ho Dec 9, 2019 06:29am
- The next round of biennial actual transaction price (ATP)-based drug price reduction is to be in effect from January 2020. It feels like the time is approaching too fast too soon. While going through hectic times with the aftermath of valsartan and ranitidine incidents, affected pharmaceutical companies, distributors and healthcare insti
- Policy
- What should Metformin do?
- by Lee, Tak-Sun Dec 9, 2019 06:27am
- The MFDS, which has undergone a series of Ranitidine and Nizatidine events, has ordered companies to assess the likelihood of impurity on all synthetic drug substances. Of these, raw materials and finished products with high potential for impurity detection should be tested immediately and reported to the MFDS if abnormal quantities are detec
- Policy
- Investigation of raw materials for Metformin in Singapore
- by Kim, Jin-Gu Dec 9, 2019 06:27am
- The three Metformin products recovered from Singapore have yet to be imported in Korea. The Singapore Ministry of Health (HSA) recently surveyed 46 locally Metformin products and recovered three of them. N-nitrosodimethylamine (NDMA) was detected above the daily allowance (96 nanograms), explains the HSA. Two controversial companies are Gl
- Company
- Reimbursement expansion of osteoporosis drug 'Prolia'
- by Chon, Seung-Hyun Dec 9, 2019 06:27am
- In the domestic osteoporosis treatment market, the prosperity of 'Prolia' continues. In the six months since the increase in health insurance benefits in April, the company has built a solitary system in the market with sales of about &8361;25 billion. Amgen's Prolia, on the 6th, reported sales of &8361;13.5 billion in the third quarter, mo
- Company
- AbbVie Skyrizi approved, a new option for psoriasis
- by Eo, Yun-Ho Dec 9, 2019 06:26am
- Patients with plaque psoriasis now has another interleukin inhibitor option. On Dec. 3, AbbVie Korea announced Korean Ministry of Food and Drug Safety (MFDS) approved its interleukin-23 (IL-23) inhibitor Skyrizi Prefilled Syringe (risankizumab) for the treatment of moderate to severe psoriasis in adult patients who are candidates for sy
- Company
- 'Jardiance' reaffirms CV benefits over DPP-4 inhibitors
- by Eo, Yun-Ho Dec 9, 2019 06:26am
- Research shows that SGLT-2 inhibitor ‘Jardiance’ has more cardiovascular benefits than DPP-4 inhibitors. Boehringer Ingelheim and Lilly are the first to analyze Jardiance’s effectiveness of the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Asia study at the International Diabetes Federation, IDF presented at the General
- Company
- Celltrion, achieved first $1 billion exports in Korea
- by Chon, Seung-Hyun Dec 9, 2019 06:26am
- Celltrion Healthcare announced on the 5th that it won '$1 Billion Export Tower award ' at the 56th Trade Day Ceremony hosted by the Korea International Trade Association. Celltrion Healthcare is the first Korean pharmaceutical bio company to surpass $1 billion in annual exports. Only five companies have received more than $1 billion towers.
- Company
- Terramycin out again, Pfizer says February next year
- by Jung, Hye-Jin Dec 9, 2019 06:26am
- Pfizer Korea’s Terramycin ophthalmic ointment (3.5 g) is out of stock yet again. Pharmacies are expecting to fall into confusion as the versatile ointment is used vastly with affordable reimbursed price for various conditions. Pfizer Korea notified distributors and pharmacies recently that the production schedule of Terramycin ophthalmic
- Hesitation of Biosimilar in the immune disease market
- by Kim, Jin-Gu Dec 6, 2019 10:40am
- In the market of TNF alpha inhibitors used to treat autoimmune diseases, domestic biosimilars are showing opposite results. While Celltrion's 'Remsima' has achieved its performance, Samsung Bioepis' Remaroche, SB4, and LG Chem's ‘Eucept' have a weak presence. According to drug research agency IQVIA on the 5th, the market size of TNF alpha
- Policy
- Reevaluation in follow-up again? VS doublecheck needed
- by Kim, Jung-Ju Dec 6, 2019 10:34am
- In the trend of reinforcing health insurance coverage, the policy of strengthening after-market insurance policy, which the government intends to strengthen as part of rational fiscal expenditure, is evaluated in various ways as well as the depth and breadth of coverage. The 'preparation criteria and methods for the evaluation of drugs', whic
